Monitoring during and after antiviral therapy for hepatitis B.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyQuantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis BLong-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BMicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirinHost immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.Correlation between hepatitis B surface antigen titers and HBV DNA levelsHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
P2860
Q26740161-9B7FB6C0-1BEB-40CE-9C4F-F2B6FECABBFCQ33590508-2489575E-41D8-4F8F-B68F-C664C9EDC237Q33721394-455DCCC5-20FE-40B1-9B03-4FF39D2F2DD0Q33939443-7E39641E-814B-43C1-8329-AE131221D31CQ34579911-5272E58F-FE91-43B1-AA89-58D60C6EBC40Q37281927-43D42AB9-B8EA-4A7E-B723-C914AD130997Q37611853-8C229E3D-E244-4858-8B15-8B2DE77D0073Q37645703-E9CCA3FC-3EDD-4F1A-B830-7322069CB2E5Q38295840-0B1A8A80-9035-4CEC-8789-90C295DD8EEAQ39152779-D3F5050C-F793-459A-AF23-E53DA0BFFCC1Q40557516-8941CB7C-BA8C-4DAA-8EDD-A64D1E9014DEQ42616157-F4F61422-96B9-48CB-A122-D87F161895D7Q42660250-05F802A6-D01C-448A-A0C4-B80170381700Q53425320-580824B0-B69A-4341-936B-AEFA5D73247E
P2860
Monitoring during and after antiviral therapy for hepatitis B.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monitoring during and after antiviral therapy for hepatitis B.
@en
Monitoring during and after antiviral therapy for hepatitis B.
@nl
type
label
Monitoring during and after antiviral therapy for hepatitis B.
@en
Monitoring during and after antiviral therapy for hepatitis B.
@nl
prefLabel
Monitoring during and after antiviral therapy for hepatitis B.
@en
Monitoring during and after antiviral therapy for hepatitis B.
@nl
P2860
P356
P1433
P1476
Monitoring during and after antiviral therapy for hepatitis B.
@en
P2093
Karin L Andersson
P2860
P304
P356
10.1002/HEP.22899
P407
P433
P577
2009-05-01T00:00:00Z